about
Increased Expression of Several Collagen Genes is Associated with Drug Resistance in Ovarian Cancer Cell LinesMicroarray-based detection and expression analysis of new genes associated with drug resistance in ovarian cancer cell linesNew and Old Genes Associated with Topotecan Resistance Development in Ovarian Cancer Cell Lines.The significance of lumican expression in ovarian cancer drug-resistant cell lines.Multiplex Gene Expression Profiling of In Vivo Isolated Circulating Tumor Cells in High-Risk Prostate Cancer Patients.New and Old Genes Associated with Primary and Established Responses to Cisplatin and Topotecan Treatment in Ovarian Cancer Cell Lines.New and Old Genes Associated with Primary and Established Responses to Paclitaxel Treatment in Ovarian Cancer Cell Lines.The Role of Matrix Gla Protein (MGP) Expression in Paclitaxel and Topotecan Resistant Ovarian Cancer Cell LinesMutual Expression of ALDH1A1, LOX, and Collagens in Ovarian Cancer Cell Lines as Combined CSCs- and ECM-Related Models of Drug Resistance DevelopmentPTPRK Expression Is Downregulated in Drug Resistant Ovarian Cancer Cell Lines, and Especially in ALDH1A1 Positive CSCs-Like PopulationsA case of bizarre posttransplant anti-glomerular basement membrane diseaseMyotilin, a New Topotecan Resistant Protein in Ovarian Cancer Cell LinesExpression of Osteoblast-Specific Factor 2 (OSF-2, Periostin) Is Associated with Drug Resistance in Ovarian Cancer Cell LinesCirculating Tumor Cells as a Marker of Disseminated Disease in Patients with Newly Diagnosed High-Risk Prostate CancerAnalysis of Circulating Tumor Cells in Patients with Non-Metastatic High-Risk Prostate Cancer before and after Radiotherapy Using Three Different Enumeration Assays
P50
Q37068010-CC0280C7-C426-4F59-97E6-C2E933A646D3Q38700421-A427C7F4-42B1-4C3C-A1B4-04A78E7B5A3EQ38709065-841B4607-3B2B-4747-9415-632393326D82Q47132524-33827403-8155-4A55-96F3-C81CB0129612Q47419489-88EA8E9D-941D-42B8-B71A-5086DA6C596DQ48190854-54241409-5F97-4402-9E6E-76BDA905AA58Q52591916-4773088C-3C62-44B9-AD51-B79B1E71D31FQ59138332-DA399DC4-AB27-4CDA-801B-3E9D394FB531Q60935573-DC930787-7DEA-4747-8A74-E115B72992D0Q64253257-CFCF341B-07D1-4994-BB2D-D04002956570Q90150250-F8550994-321D-4F60-B3E5-6C25071FD774Q90290790-E72D5B76-B996-4138-8CA2-3DBE8CA3915AQ92619180-2BAD397C-0D1B-450E-9771-A504B8C5B36DQ92634841-7873DA26-18B8-4B38-88E6-16F138316E50Q92662232-A2D1B95D-A579-4D2D-B040-32B4CAF49B51
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Monika Świerczewska
@ast
Monika Świerczewska
@en
Monika Świerczewska
@es
Monika Świerczewska
@nl
Monika Świerczewska
@sl
type
label
Monika Świerczewska
@ast
Monika Świerczewska
@en
Monika Świerczewska
@es
Monika Świerczewska
@nl
Monika Świerczewska
@sl
prefLabel
Monika Świerczewska
@ast
Monika Świerczewska
@en
Monika Świerczewska
@es
Monika Świerczewska
@nl
Monika Świerczewska
@sl
P106
P1153
38661674000
P21
P31
P496
0000-0001-6483-9524